|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
12/11/2012 10:06:53 AM
PORT WASHINGTON, N.Y., Dec. 11, 2012 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, launched the first generic version of the 500 mg strength (microsize) of Griseofulvin Tablets USP, an FDA approved generic version of Valeant Pharmaceutical's Grifulvin V®. According to IMS Health data, U.S. market sales for Griseofulvin tablets, an antifungal antibiotic that fights infections caused by fungus, were approximately $13 million for the twelve months ended June 30, 2012. The launch of the 500 mg strength of Griseofulvin tablets USP follows the previously announced launch of the first generic version of the 125mg and 250mg strengths of Ultramicrosize Griseofulvin tablets USP by Rising Pharmaceuticals in November 2012.
|
|
|
|
|
|
|
|
|
|
|